Celltrion Announces The Acquisition Of iQone Healthcare Switzerland, Further Expanding Its Expertise And Presence In Europe
Incheon ( BUSINESS WIRE ) - Celltrion (KRX:068270), a leading global biopharmaceutical company, announced the acquisition of iQone Healthcare Switzerland, a specialty pharmaceutical company focused on distribution, sales and marketing in Switzerland.
The acquisition, which is expected to close in the fourth quarter of 2024, represents a significant milestone in Celltrion's European expansion strategy. Upon completion of the transaction, iQone Healthcare Switzerland will become a wholly owned subsidiary of Celltrion Healthcare Hungary Kft. The transaction will also provide Celltrion with access to in-licensing opportunities, further strengthening its pipeline of innovative therapies.
Taehun Ha, Head of Europe and Vice President of Celltrion, Inc., emphasized the importance of the acquisition, stating: " This move represents a strategic shift in our growth strategy. While we have successfully built direct distribution networks, we are now leveraging acquisitions to accelerate our expansion in Europe. With a distribution network spanning more than 20 regions, we are well positioned to compete in the increasingly competitive biosimilars market."
He added: " As a fully integrated company, Celltrion manages every stage of the value chain - from research and development to manufacturing, sales, marketing and distribution. This integration allows us to continue and expand our stable and growing offering of high-quality biosimilars, including in Switzerland, where we aim to further consolidate our market presence and portfolio. It also underlines our commitment to leadership through local operational excellence and continuous innovation."
Laurent Massuyeau, founder and CEO of iQone Healthcare Switzerland, was optimistic: “ Our successful ten-year partnership with Celltrion has created a very solid foundation for this integration. By combining Celltrion's portfolio expertise with our established business operations, this acquisition will drive growth and improve access to important biosimilars and innovative medicines in Switzerland.
True to our values and with the support of the "iQone for You" program, an excellent service offering aimed at healthcare professionals and specifically developed for the Swiss market, we will continue to serve our customers flexibly and efficiently and bring new therapeutic options to Switzerland quickly."
About Celltrion
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea, focused on discovering, developing, manufacturing, commercializing and distributing innovative therapeutics that improve the lives of people worldwide. The company's solutions include best-in-class monoclonal antibody biosimilars such as Remsima ® , Truxima ® and Herzuma ® , enabling broader access to patients worldwide. Celltrion has also received U.S. FDA and European Commission approval for Vegzelma ® and Yuflyma ® , FDA approval for Zymfentra ® and European Commission approval for Remsima ® SC, Omlyclo ® , SteQeyma ® . For more information, visit www.celltrion.com/en-us .
About iQone Healthcare Switzerland
iQone Healthcare, a Switzerland-based specialty pharmaceutical company dedicated to commercializing biosimilars and innovative therapies for rare diseases, is committed to ensuring that therapeutic advances are accessible to Swiss patients in a timely manner and that they receive the care they need at the right time.
Through long-standing collaboration with several global pharmaceutical developers and manufacturers, iQone Healthcare offers healthcare professionals and institutions in Switzerland an ever-growing selection of leading biosimilars and innovative products.
iQone Healthcare has partnered with Celltrion as the exclusive distribution partner for Switzerland for a decade and successfully markets Celltrion’s product range, including Remsima®, Veblocema®, Truxima®, Herzuma®, Vegzelma® and Yuflyma®.
For more information, visit www.iqone-healthcare.com
Forward-looking statements
Certain information contained in this press release contains statements regarding our future business and financial performance and future events or developments affecting Celltrion Inc. and its subsidiaries that may be deemed forward-looking statements under applicable securities laws.
These statements can be identified by words such as "prepares," "hopes to," "pending," "plans," "aims," "will be launched," "prepares," "once won," "could," "with the aim of," "may," "once identified," "will," "work toward," "is due," "will be available," "has potential," the negative of these words or other variations thereof or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of the management of Celltrion Inc. and its subsidiaries, many of which are beyond its control.
Forward-looking statements are made to provide prospective investors with an opportunity to understand management's beliefs and opinions regarding the future so that they may consider those beliefs and opinions as a factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties that may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.
Although the forward-looking statements contained in this presentation are based on assumptions that management of Celltrion Inc. and its subsidiaries believe to be reasonable, there can be no assurance that the forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update any forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking statements.
The source language in which the original text is published is the official and authorized version. Translations are provided for ease of understanding. Only the language version that was originally published is legally binding. Therefore, compare translations with the original language version of the publication.
© 2024 Business Wire